BioSpace News Archive

Cerevel Therapeutics, a company dedicated to unraveling the mysteries of the brain to treat neuroscience diseases, announced the appointment of Ron Renaud as president and chief executive officer, and member of the company’s board of directors, effective June 12, 2023.

Bio-Techne Corporation reported its financial results for the third quarter ended March 31, 2023.

Caris Life Sciences®, the leading molecular science and technology company actively developing and delivering innovative solutions to revolutionize healthcare, announced that the University of Maryland Marlene and Stewart Greenebaum Comprehensive Cancer Center has joined the Caris Precision Oncology Alliance™.

EMPOWER CLINICS INC is pleased to announce that its subsidiary EPW Curesearch LLC has signed another Research Services Agreement with a leading physician and researcher who will act as a Principal Investigator supporting the provision of Pharmaceutical Research and Clinical Trials Services of the first site in Dallas, TX.

Matinas BioPharma Holdings, Inc. (NYSE American: MTNB), a clinical-stage biopharmaceutical company focused on redefining the intracellular delivery of nucleic acids and small molecules with its lipid nanocrystal (LNC) platform technology, announces that it will report first quarter 2023 financial results after market close on Wednesday, May 10, 2023.

Arvinas, Inc. announced that Sean Cassidy, Chief Financial Officer, and Randy Teel, Ph.D., Senior Vice President, Corporate and Business Development, will participate in a fireside chat at the Bank of America Securities 2023 Healthcare Conference on Tuesday, May 9 at 6:40 p.m. ET/3:40 p.m.

NeuroMetrix, Inc. (Nasdaq: NURO) today reported financial and business highlights for the quarter ended March 31, 2023.

Amarin Corporation plc (NASDAQ:AMRN), today announced financial results for the quarter ended March 31, 2023 and provided an update on the Company’s operations.

Gritstone bio, Inc., a clinical-stage biotechnology company working to develop the world’s most potent vaccines, announced it will report its first quarter 2023 financial results and provide a corporate update following market close on Thursday, May 11, 2023.

Adagio Medical, Inc., a leading innovator in catheter ablation technologies for atrial fibrillation and ventricular tachycardia, announced the completion of enrollment in its Cryocure-VT trial of ultra-low temperature cryoablation for the treatment of monomorphic ventricular tachycardias.